Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Stephens Investment Management Group LLC

Stephens Investment Management Group LLC grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 818,828 shares of the medical equipment provider's stock after acquiring an additional 15,134 shares during the quarter. Stephens Investment Management Group LLC owned about 0.35% of Hologic worth $66,702,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of HOLX. First Trust Direct Indexing L.P. increased its holdings in Hologic by 3.3% in the 1st quarter. First Trust Direct Indexing L.P. now owns 7,882 shares of the medical equipment provider's stock worth $614,000 after buying an additional 253 shares during the period. Legacy Wealth Asset Management LLC grew its stake in shares of Hologic by 16.8% during the 1st quarter. Legacy Wealth Asset Management LLC now owns 3,650 shares of the medical equipment provider's stock worth $285,000 after purchasing an additional 526 shares during the period. Norden Group LLC grew its stake in shares of Hologic by 44.0% during the 1st quarter. Norden Group LLC now owns 5,480 shares of the medical equipment provider's stock worth $427,000 after purchasing an additional 1,675 shares during the period. Sequoia Financial Advisors LLC grew its stake in shares of Hologic by 6.9% during the 1st quarter. Sequoia Financial Advisors LLC now owns 7,050 shares of the medical equipment provider's stock worth $550,000 after purchasing an additional 452 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of Hologic by 21.9% during the 1st quarter. BNP Paribas Financial Markets now owns 377,439 shares of the medical equipment provider's stock worth $29,425,000 after purchasing an additional 67,807 shares during the period. Institutional investors and hedge funds own 94.73% of the company's stock.

Hologic Trading Up 1.8 %

NASDAQ HOLX traded up $1.46 during trading on Friday, hitting $82.33. The stock had a trading volume of 1,955,948 shares, compared to its average volume of 1,574,248. The company has a market capitalization of $19.12 billion, a PE ratio of 28.03, a PEG ratio of 2.94 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The firm has a 50 day moving average price of $80.94 and a 200 day moving average price of $77.95. Hologic, Inc. has a twelve month low of $66.53 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.04. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. Hologic's revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.93 EPS. As a group, equities research analysts forecast that Hologic, Inc. will post 4.09 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HOLX shares. Stephens reaffirmed an "overweight" rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Leerink Partners decreased their target price on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Royal Bank of Canada reiterated a "sector perform" rating and set a $82.00 target price on shares of Hologic in a research report on Friday, August 16th. JPMorgan Chase & Co. increased their target price on Hologic from $91.00 to $95.00 and gave the company an "overweight" rating in a research report on Tuesday, July 30th. Finally, Evercore ISI increased their target price on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a research report on Tuesday, October 1st. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and an average price target of $87.50.

Insider Buying and Selling

In related news, insider Brandon Schnittker sold 476 shares of the company's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total transaction of $39,560.36. Following the sale, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.